Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Adagrasib for previously treated KRAS G12C mutated advanced non-small-cell lung cancer Adagrasib (MRTX-849) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Acoramidis for symptomatic transthyretin amyloid cardiomyopathy Acoramidis (AG10) Transthyretin amyloid cardiomyopathy Cardiovascular System 2023 View  |  Download
Acarizax for treating allergic rhinitis or allergic rhinoconjunctivitis in children aged 5 to 11 years old Acarizax Allergic rhinitis , Allergic rhinoconjunctivitis Immunology , Ophthalmology 2024 View  |  Download
Acalabrutinib with venetoclax for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma Acalabrutinib (Calquence; ACP-196) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Acalabrutinib with venetoclax and obinutuzumab for treating previously untreated chronic lymphocytic leukaemia Acalabrutinib (Calquence; ACP-196) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Acalabrutinib with bendamustine and rituximab for treating previously untreated mantle cell lymphoma Acalabrutinib (Calquence; ACP-196) , Bendamustine (Treanda; EP-3102; Levact; Ribomustin; bendamustine hydrochloride monohydrate; bendamustine hydrochloride) , Rituximab (MabThera; Rituxan; RG 105) Mantle cell lymphoma Haematological Cancer and Lymphomas 2022 View  |  Download
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma Acalabrutinib (Calquence; ACP-196) Mantle cell lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Acalabrutinib for relapsed/refractory Chronic lymphocytic leukaemia Acalabrutinib (Calquence; ACP-196) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2019 View  |  Download
Acalabrutinib for chronic lymphocytic leukaemia – first line Acalabrutinib (Calquence; ACP-196) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2019 View  |  Download
Abrocitinib for moderate to severe atopic dermatitis Abrocitinib (PF-04965842) Atopic dermatitis Dermatology 2020 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications